Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Infusion of Dinutuximab in High-Risk Neuroblastoma
NCT05421897Phase 2Active, not recruiting
- Sponsor
- Children's Hospital Los Angeles
- Start
- Nov 2022
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of dinutuximab in neuroblastoma, sponsored by Children's Hospital Los Angeles. Primary endpoints: Feasibility of administering rapid dinutuximab infusion in 5 hours or less on dinutuximab infusion days 1-4 in cycle 1 at 4 weeks, Average dinutuximab infusion time on dinutuximab infusion days 1-4 in cycle 1 at 4 weeks and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05421897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421897.